Related references
Note: Only part of the references are listed.Intermittent parathyroid hormone fails to stimulate osseointegration in diabetic rats
Ulrike Kuchler et al.
CLINICAL ORAL IMPLANTS RESEARCH (2011)
The Bone Marrow Microenvironment Contributes to Type I Diabetes Induced Osteoblast Death
Lindsay M. Coe et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism
Mathieu Ferron et al.
CELL (2010)
Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats
Chung-Ching Liu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone
Chung C. Liu et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Continuous Elevation of PTH Increases the Number of Osteoblasts via Both Osteoclast-Dependent and -Independent Mechanisms
Robert L. Jilka et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Streptozotocin, Type I Diabetes Severity and Bone
Katherine Motyl et al.
BIOLOGICAL PROCEDURES ONLINE (2009)
Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts
Robert L. Jilka et al.
BONE (2009)
Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair
Matthew Schnoke et al.
BONE (2009)
Role of Parathyroid Hormone-Related Protein in the Decreased Osteoblast Function in Diabetes-Related Osteopenia
Daniel Lozano et al.
ENDOCRINOLOGY (2009)
Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study
Bo Abrahamsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Rapamycin Impairs Trabecular Bone Acquisition From High-Dose But Not Low-Dose Intermittent Parathyroid Hormone Treatment
P. J. Niziolek et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Leptin Treatment Prevents Type I Diabetic Marrow Adiposity But Not Bone Loss in Mice
Katherine J. Motyl et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Bone Inflammation and Altered Gene Expression with Type I Diabetes Early Onset
Katherine J. Motyl et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation
Glenda J. Pettway et al.
BONE (2008)
Differentiation and Proliferation of Periosteal Osteoblast Progenitors Are Differentially Regulated by Estrogens and Intermittent Parathyroid Hormone Administration
Mami Ogita et al.
ENDOCRINOLOGY (2008)
Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus
John L. Fowlkes et al.
ENDOCRINOLOGY (2008)
An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?
Ernest Beng Kee Kwek et al.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2008)
Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment
George L. Barnes et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2008)
Low-energy femoral shaft fractures associated with alendronate use
Andrew S. Neviaser et al.
JOURNAL OF ORTHOPAEDIC TRAUMA (2008)
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate
Brett A. Lenart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Understanding the pathology and mechanisms of type I diabetic bone loss
Laura R. McCabe
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Type I diabetic bone phenotype is location but not gender dependent
Lindsay M. Martin et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2007)
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Robert L. Jilka
BONE (2007)
Effects of parathyroid hormone (1-34) on tibia in an adult rat model for chronic alcohol abuse
Jean D. Sibonga et al.
BONE (2007)
Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution
S.-K. Goh et al.
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME (2007)
Possible association between diabetes and bisphosphonate-related jaw osteonecrosis
Mogher Khamaisi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice
Sergiu Botolin et al.
ENDOCRINOLOGY (2007)
Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats
Russell T. Turner et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Inhibition of PPARγ prevents type I diabetic bone marrow adiposity but not bone loss
Sergiu Rotolin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways
Sergiu Botolin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength
J. Fox et al.
CALCIFIED TISSUE INTERNATIONAL (2006)
Combined treatment with a β-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice
Dominique D. Pierroz et al.
BONE (2006)
Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis
AH Tashjian et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
BMD and body composition in children and young patients affected by cystic fibrosis
ML Bianchi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
The effects of local insulin delivery on diabetic fracture healing
A Gandhi et al.
BONE (2005)
Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice
S Botolin et al.
ENDOCRINOLOGY (2005)
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34)
YM Alkhiary et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2005)
The role of hypoxia inducible factor 1α in cobalt chloride induced cell death in mouse embryonic fibroblasts
A Vengellur et al.
TOXICOLOGICAL SCIENCES (2004)
Targeted overexpression of androgen receptor in osteoblasts: Unexpected complex bone phenotype in growing animals
KM Wiren et al.
ENDOCRINOLOGY (2004)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells
S Tanaka et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts - A putative explanation for why intermittent administration is needed for bone anabolism
T Bellido et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Parathyroid hormone bone anabolic action requires Bbfa1/Runx2-dependent signaling
V Krishnan et al.
MOLECULAR ENDOCRINOLOGY (2003)
Simulated microgravity suppresses osteoblast phenotype, runx2 levels and AP-1 transactivation
C Ontiveros et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
MLO-Y4 osteocyte-like cells support osteoclast formation and activation
S Zhao et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34)
A Nakajima et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2002)
Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation
YFL Ma et al.
ENDOCRINOLOGY (2001)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone
LM Calvi et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys
DB Burr et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology
SAG Kemink et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2000)
Histomorphometric evaluation of the recovering effect of human parathyroid hormone (1-34) on bone structure and turnover in streptozotocin-induced diabetic rats
T Tsuchida et al.
CALCIFIED TISSUE INTERNATIONAL (2000)
Share Paper
